市場調查報告書

肺癌診斷的全球市場

Lung Cancer Diagnostics

出版商 Global Industry Analysts, Inc. 商品編碼 919019
出版日期 內容資訊 英文 605 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肺癌診斷的全球市場 Lung Cancer Diagnostics
出版日期: 2019年10月01日內容資訊: 英文 605 Pages
簡介

本報告提供全球肺癌診斷市場相關調查分析,提供市場概要,主要企業,市場趨勢·促進因素,全球市場預測,各地區市場分析,競爭情形相關的系統性資訊。

第1章 簡介·調查手法·調查範圍

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與發展因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
    • 美國
    • 加拿大
    • 日本
    • 中國
    • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他歐洲
    • 亞太地區
    • 澳洲
    • 印度
    • 韓國
    • 其他亞太地區
    • 南美
    • 阿根廷
    • 巴西
    • 墨西哥
    • 其他南美國家
    • 中東
    • 伊朗
    • 以色列
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東
    • 非洲

第4章 競爭企業

  • ABBOTT DIAGNOSTICS - CORE LABORATORY
  • ADMERA HEALTH
  • AGENA BIOSCIENCE, INC.
  • AGILENT TECHNOLOGIES, INC.
  • ASURAGEN, INC.
  • BGI GENOMICS CO., LTD.
  • BIOCARTIS NV
  • BIOCEPT, INC.
  • BIODESIX, INC.
  • BIOPROGNOS SL
  • BLUEPRINT GENETICS OY
  • CANCER GENETICS, INC.
  • CELLMAX LIFE, INC.
  • CELLNETIX PATHOLOGY & LABORATORIES
  • CIRCULOGENE
  • DR LAL PATHLABS
  • ENTROGEN, INC.
  • EPIGENOMICS AG
  • EXACT SCIENCES CORPORATION
  • EXOSOME DIAGNOSTICS, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • FULGENT GENETICS
  • GENEKOR MEDICAL SA
  • GUARDANT HEALTH, INC.
  • ILLUMINA, INC.
  • IMMUNOVIA AB
  • INIVATA LTD.
  • LUCENCE DIAGNOSTICS PTE LTD.
  • MEDGENOME LABS LTD.
  • MYRIAD GENETICS, INC.
  • NANOSTRING TECHNOLOGIES, INC.
  • NEOGENOMICS LABORATORIES, INC.
  • ONCIMMUNE LTD.
  • ONCOCYTE CORPORATION
  • ONCODNA SA
  • PARAGON GENOMICS, INC.
  • PILLAR BIOSCIENCES, INC.
  • PLEXBIO CO., LTD.
  • QIAGEN GMBH
  • QUEST DIAGNOSTICS, INC.
  • SAVICELL DIAGNOSTIC LTD.
  • STAGEZERO LIFE SCIENCES, LLC
  • STRAND LIFE SCIENCES PVT. LTD.
  • SWIFT BIOSCIENCES, INC.
  • SYSMEX INOSTICS, INC.
  • THERMO FISHER SCIENTIFIC, INC.
目錄
Product Code: MCP16923

Lung Cancer Diagnostics market worldwide is projected to grow by US$1.3 Billion, driven by a compounded growth of 8%. Imaging Tests, one of the segments analyzed and sized in this study, displays the potential to grow at over 7.5%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$1.6 Billion by the year 2025, Imaging Tests will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 6.6% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$45.5 Million to the region's size and clout in the next 5 to 6 years. Over US$39.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Imaging Tests will reach a market size of US$85.6 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 11.4% over the next couple of years and add approximately US$354.6 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include among others, Abbott Diagnostics - Core Laboratory; Dr Lal PathLabs; F. Hoffmann-La Roche AG; Illumina Inc.; Myriad Genetics Inc.; NanoString Technologies; NeoGenomics Laboratories Inc.; PlexBio Co., Ltd.; QIAGEN GmbH; Quest Diagnostics; Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE 1

II. EXECUTIVE SUMMARY 13

1. MARKET OVERVIEW 13

  • Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics 13
  • Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types 14
  • Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth 15
  • US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth 16

2. FOCUS ON SELECT PLAYERS 18

  • Agilent Technologies Inc. (USA) 18
  • F. Hoffmann-La Roche Ltd. (Switzerland) 18
  • Illumina, Inc. (USA) 19
  • NeoGenomics Laboratories, Inc. (USA) 19
  • QIAGEN N.V. (The Netherlands) 19
  • Thermo Fisher Scientific, Inc. (USA) 20
  • Veracyte (USA) 21

3. MARKET TRENDS & DRIVERS 22

  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses 22
  • Age-Standardized Lung Cancer Rates for Select Countries 23
  • Age-Standardized Lung Cancer Rates in Men for Select Countries 24
  • Age Standardized Lung Cancer Rates in Women for Select Countries 25
  • Lung Cancer-Specific Biomarkers to Spur Market Growth 26
  • Select Lung Cancer Biomarkers 27
  • New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019) 27
  • Advancements and Research Initiatives Provide Significant Opportunities 28
  • EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients 29
  • A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests 29
  • New Product Launches/Approvals in the Lung Cancer Diagnostics 30
  • Recent Approvals 31
  • Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs 32
  • Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years 33
  • High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer 34
  • Cigarette Consumption Per Year Per Person Across Select Countries: 2016 35
  • Top 15 Countries with the Highest Smoking Rates: 2015 36
  • Increasing Number of Awareness Programs for Lung Cancer and Symptoms 36
  • Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics 38
  • National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017 39
  • Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer 39
  • Cancer Prone Sites based on Age 40
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 40

4. GLOBAL MARKET PERSPECTIVE 41

  • TABLE 1: Lung Cancer Diagnostics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 41
  • TABLE 2: Lung Cancer Diagnostics Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 42
  • TABLE 3: Lung Cancer Diagnostics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 43
  • TABLE 4: Imaging Tests (Test) World Market by Region/Country in US$ Thousand: 2018 to 2025 44
  • TABLE 5: Imaging Tests (Test) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 45
  • TABLE 6: Imaging Tests (Test) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 46
  • TABLE 7: Sputum Cytology (Test) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 47
  • TABLE 8: Sputum Cytology (Test) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 48
  • TABLE 9: Sputum Cytology (Test) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 49
  • TABLE 10: Molecular Tests (Test) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 50
  • TABLE 11: Molecular Tests (Test) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017 51
  • TABLE 12: Molecular Tests (Test) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 52
  • TABLE 13: Biopsy (Test) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 53
  • TABLE 14: Biopsy (Test) Market Historic Review by Region/Country in US$ Thousand: 2009 to 2017 54
  • TABLE 15: Biopsy (Test) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 55
  • TABLE 16: Other Tests (Test) World Market by Region/Country in US$ Thousand: 2018 to 2025 56
  • TABLE 17: Other Tests (Test) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 57
  • TABLE 18: Other Tests (Test) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 58
  • TABLE 19: Non-Small-Cell Lung Cancer (NSCLC) (Type) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018 to 2025 59
  • TABLE 20: Non-Small-Cell Lung Cancer (NSCLC) (Type) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2009 to 2017 60
  • TABLE 21: Non-Small-Cell Lung Cancer (NSCLC) (Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 61
  • TABLE 22: Small-Cell Lung Cancer (SCLC) (Type) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2018 to 2025 62
  • TABLE 23: Small-Cell Lung Cancer (SCLC) (Type) Global Historic Demand in US$ Thousand by Region/Country: 2009 to 2017 63
  • TABLE 24: Small-Cell Lung Cancer (SCLC) (Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 64
  • TABLE 25: Hospital Laboratories (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 65
  • TABLE 26: Hospital Laboratories (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 66
  • TABLE 27: Hospital Laboratories (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025 67
  • TABLE 28: Cancer Research Institutes (End-Use) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 68
  • TABLE 29: Cancer Research Institutes (End-Use) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2009-2017 69
  • TABLE 30: Cancer Research Institutes (End-Use) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 70
  • TABLE 31: Other End-Uses (End-Use) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025 71
  • TABLE 32: Other End-Uses (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 72
  • TABLE 33: Other End-Uses (End-Use) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 73

III. MARKET ANALYSIS 74

  • GEOGRAPHIC MARKET ANALYSIS 74
  • UNITED STATES 74
    • Lung Cancer Stats 74
    • US Lung and Bronchus Cancer New Cases by Gender: 2019E 75
    • US Lung and Bronchus Cancer Deaths by Gender: 2019E 75
    • Incidence Rates* for Lung and Bronchus Cancer by Gender, 2011-2015 76
    • Death Rates* for Lung and Bronchus Cancer by Gender in the US, 2012-2016 76
    • Incidence Rates for Lung and Bronchus Cancer by Race/Ethnicity, 2011-2015 77
    • Reimbursement and Insurance Coverage for Lung Cancer Screening in the US 77
    • CY 2019 Medicare Physician Fee Payment Levels for Low Dose CT Scan (LDCT) Screening 78
    • CY 2019 Hospital Outpatient Prospective Payment System (HOPPS) Payment Levels for Low Dose CT Scan (LDCT) Screening 78
    • Oncimmune's EarlyCDT Lung to be commercialized in the US by Biodesix (2019) 78
    • Market Analytics 79
    • TABLE 34: United States Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Test: 2018 to 2025 79
    • TABLE 35: Lung Cancer Diagnostics Market in the United States by Test: A Historic Review in US$ Thousand for 2009-2017 80
    • TABLE 36: United States Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 81
    • TABLE 37: United States Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Type: 2018 to 2025 82
    • TABLE 38: Lung Cancer Diagnostics Market in the United States by Type: A Historic Review in US$ Thousand for 2009-2017 83
    • TABLE 39: United States Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 84
    • TABLE 40: United States Lung Cancer Diagnostics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 85
    • TABLE 41: Lung Cancer Diagnostics Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 86
    • TABLE 42: Lung Cancer Diagnostics Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 87
  • CANADA 88
    • TABLE 43: Canadian Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018 to 2025 88
    • TABLE 44: Canadian Lung Cancer Diagnostics Historic Market Review by Test in US$ Thousand: 2009-2017 89
    • TABLE 45: Lung Cancer Diagnostics Market in Canada: Percentage Share Breakdown of Sales by Test for 2009, 2019, and 2025 90
    • TABLE 46: Canadian Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018 to 2025 91
    • TABLE 47: Canadian Lung Cancer Diagnostics Historic Market Review by Type in US$ Thousand: 2009-2017 92
    • TABLE 48: Lung Cancer Diagnostics Market in Canada: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025 93
    • TABLE 49: Canadian Lung Cancer Diagnostics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 94
    • TABLE 50: Lung Cancer Diagnostics Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 95
    • TABLE 51: Canadian Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 96
  • JAPAN 97
    • TABLE 52: Japanese Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Test for the Period 2018-2025 97
    • TABLE 53: Lung Cancer Diagnostics Market in Japan: Historic Sales Analysis in US$ Thousand by Test for the Period 2009-2017 98
    • TABLE 54: Japanese Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 99
    • TABLE 55: Japanese Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Type for the Period 2018-2025 100
    • TABLE 56: Lung Cancer Diagnostics Market in Japan: Historic Sales Analysis in US$ Thousand by Type for the Period 2009-2017 101
    • TABLE 57: Japanese Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 102
    • TABLE 58: Japanese Demand Estimates and Forecasts for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 103
    • TABLE 59: Japanese Lung Cancer Diagnostics Market in US$ Thousand by End-Use: 2009-2017 104
    • TABLE 60: Lung Cancer Diagnostics Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 105
  • CHINA 106
    • TABLE 61: Chinese Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Test for the Period 2018-2025 106
    • TABLE 62: Lung Cancer Diagnostics Historic Market Analysis in China in US$ Thousand by Test: 2009-2017 107
    • TABLE 63: Chinese Lung Cancer Diagnostics Market by Test: Percentage Breakdown of Sales for 2009, 2019, and 2025 108
    • TABLE 64: Chinese Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Type for the Period 2018-2025 109
    • TABLE 65: Lung Cancer Diagnostics Historic Market Analysis in China in US$ Thousand by Type: 2009-2017 110
    • TABLE 66: Chinese Lung Cancer Diagnostics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 111
    • TABLE 67: Chinese Demand for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 112
    • TABLE 68: Lung Cancer Diagnostics Market Review in China in US$ Thousand by End-Use: 2009-2017 113
    • TABLE 69: Chinese Lung Cancer Diagnostics Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 114
  • EUROPE 115
    • TABLE 70: European Lung Cancer Diagnostics Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 115
    • TABLE 71: Lung Cancer Diagnostics Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 116
    • TABLE 72: European Lung Cancer Diagnostics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 117
    • TABLE 73: European Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018-2025 118
    • TABLE 74: Lung Cancer Diagnostics Market in Europe in US$ Thousand by Test: A Historic Review for the Period 2009-2017 119
    • TABLE 75: European Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 120
    • TABLE 76: European Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018-2025 121
    • TABLE 77: Lung Cancer Diagnostics Market in Europe in US$ Thousand by Type: A Historic Review for the Period 2009-2017 122
    • TABLE 78: European Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 123
    • TABLE 79: European Lung Cancer Diagnostics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 124
    • TABLE 80: Lung Cancer Diagnostics Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 125
    • TABLE 81: European Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 126
  • FRANCE 127
    • TABLE 82: Lung Cancer Diagnostics Market in France by Test: Estimates and Projections in US$ Thousand for the Period 2018-2025 127
    • TABLE 83: French Lung Cancer Diagnostics Historic Market Scenario in US$ Thousand by Test: 2009-2017 128
    • TABLE 84: French Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 129
    • TABLE 85: Lung Cancer Diagnostics Market in France by Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 130
    • TABLE 86: French Lung Cancer Diagnostics Historic Market Scenario in US$ Thousand by Type: 2009-2017 131
    • TABLE 87: French Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 132
    • TABLE 88: Lung Cancer Diagnostics Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 133
    • TABLE 89: French Lung Cancer Diagnostics Historic Market Review in US$ Thousand by End-Use: 2009-2017 134
    • TABLE 90: French Lung Cancer Diagnostics Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 135
  • GERMANY 136
    • TABLE 91: Lung Cancer Diagnostics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Test for the Period 2018-2025 136
    • TABLE 92: German Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Test: 2009-2017 137
    • TABLE 93: German Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 138
    • TABLE 94: Lung Cancer Diagnostics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Type for the Period 2018-2025 139
    • TABLE 95: German Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Type: 2009-2017 140
    • TABLE 96: German Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 141
    • TABLE 97: Lung Cancer Diagnostics Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 142
    • TABLE 98: German Lung Cancer Diagnostics Market in Retrospect in US$ Thousand by End-Use: 2009-2017 143
    • TABLE 99: Lung Cancer Diagnostics Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 144
  • ITALY 145
    • TABLE 100: Italian Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Test for the Period 2018-2025 145
    • TABLE 101: Lung Cancer Diagnostics Historic Market Analysis in Italy in US$ Thousand by Test: 2009-2017 146
    • TABLE 102: Italian Lung Cancer Diagnostics Market by Test: Percentage Breakdown of Sales for 2009, 2019, and 2025 147
    • TABLE 103: Italian Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Type for the Period 2018-2025 148
    • TABLE 104: Lung Cancer Diagnostics Historic Market Analysis in Italy in US$ Thousand by Type: 2009-2017 149
    • TABLE 105: Italian Lung Cancer Diagnostics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 150
    • TABLE 106: Italian Demand for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 151
    • TABLE 107: Lung Cancer Diagnostics Market Review in Italy in US$ Thousand by End-Use: 2009-2017 152
    • TABLE 108: Italian Lung Cancer Diagnostics Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 153
  • UNITED KINGDOM 154
    • UK Age-standardised Rate (per 100,00) of Lung Cancer Cases by Gender: 1980-2035P 154
    • TABLE 109: United Kingdom Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Test for the Period 2018-2025 155
    • TABLE 110: Lung Cancer Diagnostics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Test for the Period 2009-2017 156
    • TABLE 111: United Kingdom Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 157
    • TABLE 112: United Kingdom Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Type for the Period 2018-2025 158
    • TABLE 113: Lung Cancer Diagnostics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Type for the Period 2009-2017 159
    • TABLE 114: United Kingdom Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 160
    • TABLE 115: United Kingdom Demand Estimates and Forecasts for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 161
    • TABLE 116: United Kingdom Lung Cancer Diagnostics Market in US$ Thousand by End-Use: 2009-2017 162
    • TABLE 117: Lung Cancer Diagnostics Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 163
  • SPAIN 164
    • TABLE 118: Spanish Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018 to 2025 164
    • TABLE 119: Spanish Lung Cancer Diagnostics Historic Market Review by Test in US$ Thousand: 2009-2017 165
    • TABLE 120: Lung Cancer Diagnostics Market in Spain: Percentage Share Breakdown of Sales by Test for 2009, 2019, and 2025 166
    • TABLE 121: Spanish Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018 to 2025 167
    • TABLE 122: Spanish Lung Cancer Diagnostics Historic Market Review by Type in US$ Thousand: 2009-2017 168
    • TABLE 123: Lung Cancer Diagnostics Market in Spain: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025 169
    • TABLE 124: Spanish Lung Cancer Diagnostics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 170
    • TABLE 125: Lung Cancer Diagnostics Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 171
    • TABLE 126: Spanish Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 172
  • RUSSIA 173
    • TABLE 127: Russian Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Test: 2018 to 2025 173
    • TABLE 128: Lung Cancer Diagnostics Market in Russia by Test: A Historic Review in US$ Thousand for 2009-2017 174
    • TABLE 129: Russian Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 175
    • TABLE 130: Russian Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Type: 2018 to 2025 176
    • TABLE 131: Lung Cancer Diagnostics Market in Russia by Type: A Historic Review in US$ Thousand for 2009-2017 177
    • TABLE 132: Russian Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 178
    • TABLE 133: Russian Lung Cancer Diagnostics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 179
    • TABLE 134: Lung Cancer Diagnostics Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2009-2017 180
    • TABLE 135: Lung Cancer Diagnostics Market Share Breakdown in Russia by End-Use: 2009 VS 2019 VS 2025 181
  • REST OF EUROPE 182
    • TABLE 136: Rest of Europe Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018-2025 182
    • TABLE 137: Lung Cancer Diagnostics Market in Rest of Europe in US$ Thousand by Test: A Historic Review for the Period 2009-2017 183
    • TABLE 138: Rest of Europe Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 184
    • TABLE 139: Rest of Europe Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018-2025 185
    • TABLE 140: Lung Cancer Diagnostics Market in Rest of Europe in US$ Thousand by Type: A Historic Review for the Period 2009-2017 186
    • TABLE 141: Rest of Europe Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 187
    • TABLE 142: Rest of Europe Lung Cancer Diagnostics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 188
    • TABLE 143: Lung Cancer Diagnostics Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 189
    • TABLE 144: Rest of Europe Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 190
  • ASIA-PACIFIC 191
    • TABLE 145: Asia-Pacific Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 191
    • TABLE 146: Lung Cancer Diagnostics Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 192
    • TABLE 147: Asia-Pacific Lung Cancer Diagnostics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 193
    • TABLE 148: Lung Cancer Diagnostics Market in Asia-Pacific by Test: Estimates and Projections in US$ Thousand for the Period 2018-2025 194
    • TABLE 149: Asia-Pacific Lung Cancer Diagnostics Historic Market Scenario in US$ Thousand by Test: 2009-2017 195
    • TABLE 150: Asia-Pacific Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 196
    • TABLE 151: Lung Cancer Diagnostics Market in Asia-Pacific by Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 197
    • TABLE 152: Asia-Pacific Lung Cancer Diagnostics Historic Market Scenario in US$ Thousand by Type: 2009-2017 198
    • TABLE 153: Asia-Pacific Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 199
    • TABLE 154: Lung Cancer Diagnostics Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 200
    • TABLE 155: Asia-Pacific Lung Cancer Diagnostics Historic Market Review in US$ Thousand by End-Use: 2009-2017 201
    • TABLE 156: Asia-Pacific Lung Cancer Diagnostics Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 202
  • AUSTRALIA 203
    • TABLE 157: Lung Cancer Diagnostics Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Test for the Period 2018-2025 203
    • TABLE 158: Australian Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Test: 2009-2017 204
    • TABLE 159: Australian Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 205
    • TABLE 160: Lung Cancer Diagnostics Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Type for the Period 2018-2025 206
    • TABLE 161: Australian Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Type: 2009-2017 207
    • TABLE 162: Australian Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 208
    • TABLE 163: Lung Cancer Diagnostics Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 209
    • TABLE 164: Australian Lung Cancer Diagnostics Market in Retrospect in US$ Thousand by End-Use: 2009-2017 210
    • TABLE 165: Lung Cancer Diagnostics Market Share Distribution in Australia by End-Use: 2009 VS 2019 VS 2025 211
  • INDIA 212
    • Rise in Incidence of Lung Cancer in India 212
    • New Cancer Cases in India by Site: 2018 212
    • Market Analytics 213
    • TABLE 166: Indian Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018 to 2025 213
    • TABLE 167: Indian Lung Cancer Diagnostics Historic Market Review by Test in US$ Thousand: 2009-2017 214
    • TABLE 168: Lung Cancer Diagnostics Market in India: Percentage Share Breakdown of Sales by Test for 2009, 2019, and 2025 215
    • TABLE 169: Indian Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018 to 2025 216
    • TABLE 170: Indian Lung Cancer Diagnostics Historic Market Review by Type in US$ Thousand: 2009-2017 217
    • TABLE 171: Lung Cancer Diagnostics Market in India: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025 218
    • TABLE 172: Indian Lung Cancer Diagnostics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 219
    • TABLE 173: Lung Cancer Diagnostics Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 220
    • TABLE 174: Indian Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 221
  • SOUTH KOREA 222
    • TABLE 175: Lung Cancer Diagnostics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Test for the Period 2018-2025 222
    • TABLE 176: South Korean Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Test: 2009-2017 223
    • TABLE 177: Lung Cancer Diagnostics Market Share Distribution in South Korea by Test: 2009 VS 2019 VS 2025 224
    • TABLE 178: Lung Cancer Diagnostics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Type for the Period 2018-2025 225
    • TABLE 179: South Korean Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Type: 2009-2017 226
    • TABLE 180: Lung Cancer Diagnostics Market Share Distribution in South Korea by Type: 2009 VS 2019 VS 2025 227
    • TABLE 181: Lung Cancer Diagnostics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 228
    • TABLE 182: South Korean Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 229
    • TABLE 183: Lung Cancer Diagnostics Market Share Distribution in South Korea by End-Use: 2009 VS 2019 VS 2025 230
  • REST OF ASIA-PACIFIC 231
    • TABLE 184: Rest of Asia-Pacific Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Test for the Period 2018-2025 231
    • TABLE 185: Lung Cancer Diagnostics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Test for the Period 2009-2017 232
    • TABLE 186: Rest of Asia-Pacific Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 233
    • TABLE 187: Rest of Asia-Pacific Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Type for the Period 2018-2025 234
    • TABLE 188: Lung Cancer Diagnostics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Type for the Period 2009-2017 235
    • TABLE 189: Rest of Asia-Pacific Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 236
    • TABLE 190: Rest of Asia-Pacific Demand Estimates and Forecasts for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 237
    • TABLE 191: Rest of Asia-Pacific Lung Cancer Diagnostics Market in US$ Thousand by End-Use: 2009-2017 238
    • TABLE 192: Lung Cancer Diagnostics Market Share Shift in Rest of Asia-Pacific by End-Use: 2009 VS 2019 VS 2025 239
  • LATIN AMERICA 240
    • TABLE 193: Latin American Lung Cancer Diagnostics Market Trends by Region/Country in US$ Thousand: 2018-2025 240
    • TABLE 194: Lung Cancer Diagnostics Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 241
    • TABLE 195: Latin American Lung Cancer Diagnostics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 242
    • TABLE 196: Latin American Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Test for the Period 2018-2025 243
    • TABLE 197: Lung Cancer Diagnostics Historic Market Analysis in Latin America in US$ Thousand by Test: 2009-2017 244
    • TABLE 198: Latin American Lung Cancer Diagnostics Market by Test: Percentage Breakdown of Sales for 2009, 2019, and 2025 245
    • TABLE 199: Latin American Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Type for the Period 2018-2025 246
    • TABLE 200: Lung Cancer Diagnostics Historic Market Analysis in Latin America in US$ Thousand by Type: 2009-2017 247
    • TABLE 201: Latin American Lung Cancer Diagnostics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 248
    • TABLE 202: Latin American Demand for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 249
    • TABLE 203: Lung Cancer Diagnostics Market Review in Latin America in US$ Thousand by End-Use: 2009-2017 250
    • TABLE 204: Latin American Lung Cancer Diagnostics Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 251
  • ARGENTINA 252
    • TABLE 205: Argentinean Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018-2025 252
    • TABLE 206: Lung Cancer Diagnostics Market in Argentina in US$ Thousand by Test: A Historic Review for the Period 2009-2017 253
    • TABLE 207: Argentinean Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 254
    • TABLE 208: Argentinean Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018-2025 255
    • TABLE 209: Lung Cancer Diagnostics Market in Argentina in US$ Thousand by Type: A Historic Review for the Period 2009-2017 256
    • TABLE 210: Argentinean Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 257
    • TABLE 211: Argentinean Lung Cancer Diagnostics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 258
    • TABLE 212: Lung Cancer Diagnostics Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 259
    • TABLE 213: Argentinean Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 260
  • BRAZIL 261
    • TABLE 214: Lung Cancer Diagnostics Market in Brazil by Test: Estimates and Projections in US$ Thousand for the Period 2018-2025 261
    • TABLE 215: Brazilian Lung Cancer Diagnostics Historic Market Scenario in US$ Thousand by Test: 2009-2017 262
    • TABLE 216: Brazilian Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 263
    • TABLE 217: Lung Cancer Diagnostics Market in Brazil by Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 264
    • TABLE 218: Brazilian Lung Cancer Diagnostics Historic Market Scenario in US$ Thousand by Type: 2009-2017 265
    • TABLE 219: Brazilian Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 266
    • TABLE 220: Lung Cancer Diagnostics Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 267
    • TABLE 221: Brazilian Lung Cancer Diagnostics Historic Market Review in US$ Thousand by End-Use: 2009-2017 268
    • TABLE 222: Brazilian Lung Cancer Diagnostics Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 269
  • MEXICO 270
    • TABLE 223: Lung Cancer Diagnostics Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Test for the Period 2018-2025 270
    • TABLE 224: Mexican Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Test: 2009-2017 271
    • TABLE 225: Mexican Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 272
    • TABLE 226: Lung Cancer Diagnostics Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Type for the Period 2018-2025 273
    • TABLE 227: Mexican Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Type: 2009-2017 274
    • TABLE 228: Mexican Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 275
    • TABLE 229: Lung Cancer Diagnostics Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 276
    • TABLE 230: Mexican Lung Cancer Diagnostics Market in Retrospect in US$ Thousand by End-Use: 2009-2017 277
    • TABLE 231: Lung Cancer Diagnostics Market Share Distribution in Mexico by End-Use: 2009 VS 2019 VS 2025 278
  • REST OF LATIN AMERICA 279
    • TABLE 232: Rest of Latin America Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Test: 2018 to 2025 279
    • TABLE 233: Lung Cancer Diagnostics Market in Rest of Latin America by Test: A Historic Review in US$ Thousand for 2009-2017 280
    • TABLE 234: Rest of Latin America Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 281
    • TABLE 235: Rest of Latin America Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Type: 2018 to 2025 282
    • TABLE 236: Lung Cancer Diagnostics Market in Rest of Latin America by Type: A Historic Review in US$ Thousand for 2009-2017 283
    • TABLE 237: Rest of Latin America Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 284
    • TABLE 238: Rest of Latin America Lung Cancer Diagnostics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 285
    • TABLE 239: Lung Cancer Diagnostics Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2009-2017 286
    • TABLE 240: Lung Cancer Diagnostics Market Share Breakdown in Rest of Latin America by End-Use: 2009 VS 2019 VS 2025 287
  • MIDDLE EAST 288
    • TABLE 241: The Middle East Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 288
    • TABLE 242: Lung Cancer Diagnostics Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 289
    • TABLE 243: The Middle East Lung Cancer Diagnostics Market Share Breakdown by Region/Country: 2009, 2019, and 2025 290
    • TABLE 244: The Middle East Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018 to 2025 291
    • TABLE 245: The Middle East Lung Cancer Diagnostics Historic Market by Test in US$ Thousand: 2009-2017 292
    • TABLE 246: Lung Cancer Diagnostics Market in the Middle East: Percentage Share Breakdown of Sales by Test for 2009, 2019, and 2025 293
    • TABLE 247: The Middle East Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018 to 2025 294
    • TABLE 248: The Middle East Lung Cancer Diagnostics Historic Market by Type in US$ Thousand: 2009-2017 295
    • TABLE 249: Lung Cancer Diagnostics Market in the Middle East: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025 296
    • TABLE 250: The Middle East Lung Cancer Diagnostics Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2018 to 2025 297
    • TABLE 251: Lung Cancer Diagnostics Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 298
    • TABLE 252: The Middle East Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 299
  • IRAN 300
    • TABLE 253: Iranian Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Test for the Period 2018-2025 300
    • TABLE 254: Lung Cancer Diagnostics Market in Iran: Historic Sales Analysis in US$ Thousand by Test for the Period 2009-2017 301
    • TABLE 255: Iranian Lung Cancer Diagnostics Market Share Analysis by Test: 2009 VS 2019 VS 2025 302
    • TABLE 256: Iranian Market for Lung Cancer Diagnostics: Annual Sales Estimates and Projections in US$ Thousand by Type for the Period 2018-2025 303
    • TABLE 257: Lung Cancer Diagnostics Market in Iran: Historic Sales Analysis in US$ Thousand by Type for the Period 2009-2017 304
    • TABLE 258: Iranian Lung Cancer Diagnostics Market Share Analysis by Type: 2009 VS 2019 VS 2025 305
    • TABLE 259: Iranian Demand Estimates and Forecasts for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 306
    • TABLE 260: Iranian Lung Cancer Diagnostics Market in US$ Thousand by End-Use: 2009-2017 307
    • TABLE 261: Lung Cancer Diagnostics Market Share Shift in Iran by End-Use: 2009 VS 2019 VS 2025 308
  • ISRAEL 309
    • TABLE 262: Israeli Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Test: 2018-2025 309
    • TABLE 263: Lung Cancer Diagnostics Market in Israel in US$ Thousand by Test: A Historic Review for the Period 2009-2017 310
    • TABLE 264: Israeli Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 311
    • TABLE 265: Israeli Lung Cancer Diagnostics Market Estimates and Forecasts in US$ Thousand by Type: 2018-2025 312
    • TABLE 266: Lung Cancer Diagnostics Market in Israel in US$ Thousand by Type: A Historic Review for the Period 2009-2017 313
    • TABLE 267: Israeli Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 314
    • TABLE 268: Israeli Lung Cancer Diagnostics Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 315
    • TABLE 269: Lung Cancer Diagnostics Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 316
    • TABLE 270: Israeli Lung Cancer Diagnostics Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 317
  • SAUDI ARABIA 318
    • TABLE 271: Saudi Arabian Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Test for the Period 2018-2025 318
    • TABLE 272: Lung Cancer Diagnostics Historic Market Analysis in Saudi Arabia in US$ Thousand by Test: 2009-2017 319
    • TABLE 273: Saudi Arabian Lung Cancer Diagnostics Market by Test: Percentage Breakdown of Sales for 2009, 2019, and 2025 320
    • TABLE 274: Saudi Arabian Lung Cancer Diagnostics Market Growth Prospects in US$ Thousand by Type for the Period 2018-2025 321
    • TABLE 275: Lung Cancer Diagnostics Historic Market Analysis in Saudi Arabia in US$ Thousand by Type: 2009-2017 322
    • TABLE 276: Saudi Arabian Lung Cancer Diagnostics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 323
    • TABLE 277: Saudi Arabian Demand for Lung Cancer Diagnostics in US$ Thousand by End-Use: 2018 to 2025 324
    • TABLE 278: Lung Cancer Diagnostics Market Review in Saudi Arabia in US$ Thousand by End-Use: 2009-2017 325
    • TABLE 279: Saudi Arabian Lung Cancer Diagnostics Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 326
  • UNITED ARAB EMIRATES 327
    • TABLE 280: Lung Cancer Diagnostics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Test for the Period 2018-2025 327
    • TABLE 281: United Arab Emirates Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Test: 2009-2017 328
    • TABLE 282: Lung Cancer Diagnostics Market Share Distribution in United Arab Emirates by Test: 2009 VS 2019 VS 2025 329
    • TABLE 283: Lung Cancer Diagnostics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Type for the Period 2018-2025 330
    • TABLE 284: United Arab Emirates Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Type: 2009-2017 331
    • TABLE 285: Lung Cancer Diagnostics Market Share Distribution in United Arab Emirates by Type: 2009 VS 2019 VS 2025 332
    • TABLE 286: Lung Cancer Diagnostics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 333
    • TABLE 287: United Arab Emirates Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 334
    • TABLE 288: Lung Cancer Diagnostics Market Share Distribution in United Arab Emirates by End-Use: 2009 VS 2019 VS 2025 335
  • REST OF MIDDLE EAST 336
    • TABLE 289: Lung Cancer Diagnostics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Test for the Period 2018-2025 336
    • TABLE 290: Rest of Middle East Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Test: 2009-2017 337
    • TABLE 291: Rest of Middle East Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 338
    • TABLE 292: Lung Cancer Diagnostics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Type for the Period 2018-2025 339
    • TABLE 293: Rest of Middle East Lung Cancer Diagnostics Historic Market Analysis in US$ Thousand by Type: 2009-2017 340
    • TABLE 294: Rest of Middle East Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 341
    • TABLE 295: Lung Cancer Diagnostics Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 342
    • TABLE 296: Rest of Middle East Lung Cancer Diagnostics Market in Retrospect in US$ Thousand by End-Use: 2009-2017 343
    • TABLE 297: Lung Cancer Diagnostics Market Share Distribution in Rest of Middle East by End-Use: 2009 VS 2019 VS 2025 344
  • AFRICA 345
    • TABLE 298: African Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Test: 2018 to 2025 345
    • TABLE 299: Lung Cancer Diagnostics Market in Africa by Test: A Historic Review in US$ Thousand for 2009-2017 346
    • TABLE 300: African Lung Cancer Diagnostics Market Share Breakdown by Test: 2009 VS 2019 VS 2025 347
    • TABLE 301: African Lung Cancer Diagnostics Market Estimates and Projections in US$ Thousand by Type: 2018 to 2025 348
    • TABLE 302: Lung Cancer Diagnostics Market in Africa by Type: A Historic Review in US$ Thousand for 2009-2017 349
    • TABLE 303: African Lung Cancer Diagnostics Market Share Breakdown by Type: 2009 VS 2019 VS 2025 350
    • TABLE 304: African Lung Cancer Diagnostics Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 351
    • TABLE 305: Lung Cancer Diagnostics Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2009-2017 352
    • TABLE 306: Lung Cancer Diagnostics Market Share Breakdown in Africa by End-Use: 2009 VS 2019 VS 2025 353

IV. COMPETITION 354

1. ABBOTT DIAGNOSTICS - CORE LABORATORY 354

2. ADMERA HEALTH 355

3. AGENA BIOSCIENCE, INC. 357

4. AGILENT TECHNOLOGIES, INC. 359

5. ASURAGEN, INC. 370

6. BGI GENOMICS CO., LTD. 374

7. BIOCARTIS NV 396

8. BIOCEPT, INC. 402

9. BIODESIX, INC. 410

10. BIOPROGNOS SL 412

11. BLUEPRINT GENETICS OY 413

12. CANCER GENETICS, INC. 417

13. CELLMAX LIFE, INC. 424

14. CELLNETIX PATHOLOGY & LABORATORIES 426

15. CIRCULOGENE 429

16. DR LAL PATHLABS 431

17. ENTROGEN, INC. 432

18. EPIGENOMICS AG 434

19. EXACT SCIENCES CORPORATION 438

20. EXOSOME DIAGNOSTICS, INC. 443

21. F. HOFFMANN-LA ROCHE LTD. 445

  • ROCHE DIAGNOSTICS 453

22. FULGENT GENETICS 454

23. GENEKOR MEDICAL SA 460

24. GUARDANT HEALTH, INC. 463

25. ILLUMINA, INC. 470

26. IMMUNOVIA AB 476

27. INIVATA LTD. 480

28. LUCENCE DIAGNOSTICS PTE LTD. 483

29. MEDGENOME LABS LTD. 486

30. MYRIAD GENETICS, INC. 489

31. NANOSTRING TECHNOLOGIES, INC. 495

32. NEOGENOMICS LABORATORIES, INC. 503

33. ONCIMMUNE LTD. 508

34. ONCOCYTE CORPORATION 515

35. ONCODNA SA 520

36. PARAGON GENOMICS, INC. 525

37. PILLAR BIOSCIENCES, INC. 527

38. PLEXBIO CO., LTD. 531

39. QIAGEN GMBH 537

40. QUEST DIAGNOSTICS, INC. 551

41. SAVICELL DIAGNOSTIC LTD. 557

42. STAGEZERO LIFE SCIENCES, LLC 558

43. STRAND LIFE SCIENCES PVT. LTD. 563

44. SWIFT BIOSCIENCES, INC. 565

45. SYSMEX INOSTICS, INC. 570

  • SYSMEX EUROPE GMBH 572

46. THERMO FISHER SCIENTIFIC, INC. 574

  • LUNG CANCER DIAGNOSTICS MCP16923
  • CONTENTS
Back to Top